tumour heterogeneity clinic 
recent therapeutic advances oncology driven identification tumour genotype variations patients called interpatient heterogeneity predict response patients targeted treatments subpopulations cancer cells unique genomes patient may exist across different geographical regions tumour evolve time called intratumour heterogeneity sequencing technologies can used characterize intratumour heterogeneity diagnosis monitor clonal dynamics treatment identify emergence clinical resistance disease progression genetic interpatient intratumour heterogeneity can pose challenges design clinical trials use data 
